Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
C1q-blocking antibody (classical complement inhibitor)

tanruprubart

An investigational treatment for Guillain-Barré Syndrome.

Phase 3by Annexon Biosciences
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify tanruprubart wherever you encounter it, plus the key facts at a glance.

Generic name
tanruprubart
Development code
ANX005
Drug class
C1q-blocking antibody (classical complement inhibitor)
Manufacturer
Annexon Biosciences
How it's taken
One infusion into a vein, in a trial only

An investigational antibody from Annexon Biosciences, given once as an infusion into a vein, that blocks C1q, the protein that starts the classical complement pathway[5][11].

  • Tanruprubart, first called ANX005, met the main goal of a Phase 3 trial in Guillain-Barré syndrome (GBS) at its lower dose, run in Bangladesh and the Philippines, according to Annexon[9][2].
  • Annexon submitted it for approval in the European Union in January 2026 and said on November 9, 2026 that it expects to submit to the FDA in the fourth quarter of 2026[6][4].
  • Annexon described that European application as its first regulatory submission, so tanruprubart is not approved anywhere[6].
Follow tanruprubart by email

We'll email you when the FDA acts on tanruprubart and when new trials for Guillain-Barré Syndrome open. Unsubscribe anytime.

You'll get, for Guillain-Barré Syndrome:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where tanruprubart fits

Tanruprubart is an experimental single-infusion C1q-blocking antibody from Annexon Biosciences for Guillain-Barré syndrome (GBS), with a completed Phase 3 trial, a European application under review and a US application planned for the fourth quarter of 2026[4].

  • No medicine is FDA approved for GBS, according to Annexon[6].
  • Plasma exchange and IVIG are the standard treatments for GBS, and an American Academy of Neurology practice parameter found that each speeds recovery, that their effects are equivalent, and that steroids alone do not help[13].
  • Other studies on ClinicalTrials.gov include a planned argenx Phase 2 trial of empasiprubart added to IVIG[3].
  • The tanruprubart Phase 3 trial compared it only with placebo, in people who had not received IVIG or plasma exchange, and the comparison with IVIG or plasma exchange came from matching patients across separate studies rather than a randomized trial[2][8].
  • FORWARD excludes people treated with IVIG or plasma exchange within 90 days, so a question to bring to the neurologist in the first days of GBS is whether a FORWARD site is close enough to fit the 10-day window[1].

How tanruprubart works

In GBS, the immune system attacks the nerves outside the brain and spinal cord, sometimes after an infection, surgery or a vaccination, and weakness or tingling usually starts in the legs and can spread to the upper body; in severe cases a person needs a machine to breathe, according to MedlinePlus[14]. A 2025 review in Frontiers in Neurology explains that, after an infection, the body can make antibodies that cross-react with the coating (myelin) and the long fibers (axons) of these nerves[12].

Those antibodies switch on the classical complement pathway, a chain of blood proteins that the review says plays a key role in the nerve injury[12].

C1q is the complement protein that binds to antibodies and starts the classical pathway, which is why the review describes it as a proposed treatment target in GBS[12]. Tanruprubart is an antibody designed to block C1q and so stop that pathway at its first step[11][12]. In the Phase 1 study, the antibody blocked C1q and lowered neurofilament light chain, a blood marker of nerve damage, and the authors reported that clinical measures improved most at doses that blocked C1q in the blood for at least a week[11].

FORWARD gives the drug as a single infusion within 10 days of the start of weakness[1].

Clinical trial results

The Phase 3 trial (NCT04701164) randomly assigned 241 people with GBS in Bangladesh and the Philippines, BioSpace reported on June 4, 2024 (ClinicalTrials.gov lists 242 enrolled), to a single infusion of tanruprubart 30mg/kg, tanruprubart 75mg/kg or placebo[10][2]. Neither participants nor their doctors knew which, according to ClinicalTrials.gov[2].

People had to start treatment within 10 days of the onset of weakness, have a GBS disability score of 3 to 5, on a scale where higher numbers mean more disability, and not have received IVIG or plasma exchange[2]. The main measure was the GBS disability score at week 8[2]. Annexon reported that people on 30mg/kg were 2.41 times as likely as those on placebo to be in a better disability state at week 8[9].

Annexon also reported that people on 30mg/kg walked on their own a median of 31 days sooner (56 days against 87), came off a ventilator 28 days sooner (20 days against 48), and were more often fully recovered at week 26 (21.5% against 8.6%)[9]. The 75mg/kg dose was not statistically better than placebo on the main measure, according to BioSpace[10]. These results have not been published in a peer-reviewed journal.

Annexon also compared 79 Phase 3 patients on 30mg/kg with 79 patients from the International GBS Outcome Study (IGOS), a large observational study, who were treated with IVIG or plasma exchange and matched on muscle strength and disability before treatment[8]. Annexon reported that the tanruprubart group gained more than 10 more points of muscle strength by week 1, was about twice as likely to be in a better disability state at week 8, and needed a ventilator about half as often (15 of 79 against 32 of 79)[8].

This was a matched comparison of separate studies, not a randomized trial.

FORWARD (NCT07020819) is an open-label Phase 3 study in the United States and Europe in which everyone receives tanruprubart[1]. It plans to enroll about 30 people aged 8 to 85, and its main measures are drug levels in the blood over the first 15 days, with C1q levels and muscle strength at week 1 as secondary measures[1]. Annexon said on November 9, 2026 that 18 people aged 12 to 78 had been treated so far, and Annexon reported functional outcomes, complete target engagement with C1q and a generally well-tolerated safety profile[4].

ClinicalTrials.gov lists an estimated primary completion of May 31, 2027[1].

Main registered trial: NCT07020819 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations

Annexon reported in June 2024 that a single infusion was generally well tolerated in the Phase 3 trial, with mostly mild to moderate side effects, a safety profile similar to placebo and no increase in infections, and that no vaccines or preventive antibiotics were needed[9]. Annexon has not published side effect rates by type from the Phase 3 trial, and ClinicalTrials.gov had no posted results on November 17, 2026[2].

In the published Phase 1 study of 50 people in Bangladesh, 38 on tanruprubart and 12 on placebo, the drug was well tolerated at every dose with no dose-limiting side effects[11]. Annexon said on November 9, 2026 that tanruprubart was generally well tolerated in the first 18 people treated in the FORWARD study[4].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking tanruprubart

Given once, in trials only, as an infusion into a vein[1]. The FORWARD study gives a single 30mg/kg infusion on day 1, within 10 days of the start of GBS weakness[1]. The Phase 3 trial tested single infusions of 30mg/kg and 75mg/kg against placebo, and the 30mg/kg dose met the main goal[9][10]. Any approved dose would be set by an FDA label.

Development history

The Phase 3 trial began in December 2020, and the Phase 1 study results were published in the Journal of the Peripheral Nervous System in March 2025[2][11]. Annexon announced on June 4, 2024 that the Phase 3 trial met its main goal and presented fuller results at the Peripheral Nerve Society meeting, announced June 25, 2024[10][9]. On December 16, 2024 Annexon reported its real-world comparison with IGOS patients and said it would support a US submission[8].

No US submission had been announced as of November 17, 2026, and Annexon's November 9, 2026 release still describes it as coming this quarter[4]. By August 2025 Annexon was calling the drug tanruprubart (formerly ANX005), and said it was working with the FDA to gain clarity on what it called the generalizability package, which included a real-world study matching its Southeast Asian Phase 3 patients with Western patients treated with IVIG or plasma exchange[7].

The FORWARD study began in September 2025 to add US and European data, including in children[1][7]. Annexon announced on January 8, 2026 that it had submitted a Marketing Authorisation Application to the European Medicines Agency, its first regulatory submission[6]. On November 9, 2026 Annexon said the European review was underway and that it expected to submit to the FDA in the fourth quarter of 2026 with US and European data from FORWARD[4]. Annexon states that tanruprubart has FDA Fast Track and Orphan Drug designations and an EMA orphan designation for GBS[6][8].

Access and eligibility

Manufacturer
Annexon Biosciences
Eligibility requirement

Not approved, and available only in a trial. FORWARD is recruiting people aged 8 to 85 with GBS whose weakness started no more than 10 days before the infusion and who have a GBS disability score of 3, 4 or 5, on a scale where higher numbers mean more disability[1]. It leaves out people who had plasma exchange or IVIG within 90 days, or plan to, and forms of GBS that do not weaken the arms or legs[1]. ClinicalTrials.gov lists 22 recruiting US sites in 15 states and Washington, DC, among 30 sites that also include Denmark, France, Spain and the United Kingdom[1]. Because the 10-day window is short, families can ask the treating neurologist early whether a FORWARD site is nearby.

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Ask anything about tanruprubart
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Guillain-Barré Syndrome trials

Common questions about tanruprubart

▸What is tanruprubart?

An investigational antibody from Annexon Biosciences, given once as an infusion into a vein, that blocks C1q, the protein that starts the classical complement pathway[5][11]. Tanruprubart, first called ANX005, met the main goal of a Phase 3 trial in Guillain-Barré syndrome (GBS) at its lower dose, run in Bangladesh and the Philippines, according to Annexon[9][2]. Annexon submitted it for approval in the European Union in January 2026 and said on November 9, 2026 that it expects to submit to the FDA in the fourth quarter of 2026[6][4]. Annexon described that European application as its first regulatory submission, so tanruprubart is not approved anywhere[6].

▸How does tanruprubart work?

In GBS, the immune system attacks the nerves outside the brain and spinal cord, sometimes after an infection, surgery or a vaccination, and weakness or tingling usually starts in the legs and can spread to the upper body; in severe cases a person needs a machine to breathe, according to MedlinePlus[14]. A 2025 review in Frontiers in Neurology explains that, after an infection, the body can make antibodies that cross-react with the coating (myelin) and the long fibers (axons) of these nerves[12]. Those antibodies switch on the classical complement pathway, a chain of blood proteins that the review says plays a key role in the nerve injury[12].

C1q is the complement protein that binds to antibodies and starts the classical pathway, which is why the review describes it as a proposed treatment target in GBS[12]. Tanruprubart is an antibody designed to block C1q and so stop that pathway at its first step[11][12]. In the Phase 1 study, the antibody blocked C1q and lowered neurofilament light chain, a blood marker of nerve damage, and the authors reported that clinical measures improved most at doses that blocked C1q in the blood for at least a week[11]. FORWARD gives the drug as a single infusion within 10 days of the start of weakness[1].

▸What are the side effects of tanruprubart?

Annexon reported in June 2024 that a single infusion was generally well tolerated in the Phase 3 trial, with mostly mild to moderate side effects, a safety profile similar to placebo and no increase in infections, and that no vaccines or preventive antibiotics were needed[9]. Annexon has not published side effect rates by type from the Phase 3 trial, and ClinicalTrials.gov had no posted results on November 17, 2026[2]. In the published Phase 1 study of 50 people in Bangladesh, 38 on tanruprubart and 12 on placebo, the drug was well tolerated at every dose with no dose-limiting side effects[11]. Annexon said on November 9, 2026 that tanruprubart was generally well tolerated in the first 18 people treated in the FORWARD study[4].

▸How is tanruprubart taken?

Given once, in trials only, as an infusion into a vein[1]. The FORWARD study gives a single 30mg/kg infusion on day 1, within 10 days of the start of GBS weakness[1]. The Phase 3 trial tested single infusions of 30mg/kg and 75mg/kg against placebo, and the 30mg/kg dose met the main goal[9][10]. Any approved dose would be set by an FDA label.

▸Is tanruprubart FDA approved?

tanruprubart is currently in phase 3 clinical trials for Guillain-Barré Syndrome. It has not yet received FDA approval.

▸Is tanruprubart FDA approved for Guillain-Barré syndrome?

No. Tanruprubart (ANX005) is an experimental antibody, and Annexon said on November 9, 2026 that it expects to submit it to the FDA in the fourth quarter of 2026.

Europe: An application has been under review at the European Medicines Agency since January 2026.

Designations: FDA Fast Track and Orphan Drug, according to Annexon.

Today's treatment: IVIG or plasma exchange.

Source: Annexon, November 9, 2026 and Annexon EU application release

▸What did the tanruprubart Phase 3 trial show?

Annexon reported that people given 30mg/kg were 2.41 times as likely as those on placebo to be in a better disability state at week 8, the main measure.

Walking: Median of 56 days to walk on their own, against 87 on placebo.

Full recovery at week 26: 21.5% against 8.6%.

Higher dose: 75mg/kg was not statistically better than placebo on the main measure, BioSpace reported.

Where: Bangladesh and the Philippines, in people not given IVIG or plasma exchange.

Source: Annexon, June 25, 2024 and BioSpace, June 4, 2024

▸Why is Annexon running the FORWARD study before applying to the FDA?

The Phase 3 trial ran only in Bangladesh and the Philippines, and Annexon said in August 2025 that it was working with the FDA on a generalizability package comparing those results with Western patients.

FORWARD: Open-label, about 30 people aged 8 to 85 in the US and Europe, single 30mg/kg infusion.

Progress: 18 people treated as of November 9, 2026.

Source: Annexon, August 14, 2025 and ClinicalTrials.gov NCT07020819

▸Who can join the tanruprubart FORWARD study?

People aged 8 to 85 with GBS whose weakness began no more than 10 days before the infusion and who have a GBS disability score of 3, 4 or 5.

Not eligible: IVIG or plasma exchange within 90 days, or forms of GBS that do not weaken the arms or legs.

US sites: 22 recruiting, in 15 states and Washington, DC.

Source: ClinicalTrials.gov NCT07020819

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. ClinicalTrials.gov. An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barré Syndrome. https://clinicaltrials.gov/study/NCT07020819
  2. ClinicalTrials.gov. A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome. https://clinicaltrials.gov/study/NCT04701164
  3. ClinicalTrials.gov. A Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Efficacy and Safety of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome. https://clinicaltrials.gov/study/NCT07821762
  4. Annexon Biosciences via BioSpace (GlobeNewswire) · 2026-11-09. Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones. https://www.biospace.com/press-releases/annexon-reports-third-quarter-2026-financial-results-business-updates-and-key-anticipated-milestones
  5. Annexon Biosciences via BioSpace (GlobeNewswire) · 2026-08-06. Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week. https://www.biospace.com/press-releases/annexon-reports-first-u-s-and-european-patient-cohort-of-gbs-forward-study-demonstrated-rapid-positive-clinical-responses-in-all-tanruprubart-treated-patients-within-one-week
  6. Annexon Biosciences via BioSpace (GlobeNewswire) · 2026-01-08. Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome. https://www.biospace.com/press-releases/annexon-submits-tanruprubart-marketing-authorization-application-to-the-european-medicines-agency-for-guillain-barre-syndrome
  7. Annexon Biosciences via BioSpace (GlobeNewswire) · 2025-08-14. Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones. https://www.biospace.com/press-releases/annexon-reports-second-quarter-2025-financial-results-portfolio-progress-and-key-anticipated-milestones
  8. Annexon Biosciences via BioSpace (GlobeNewswire) · 2024-12-16. Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS). https://www.biospace.com/press-releases/annexon-announces-positive-topline-results-from-real-world-evidence-study-comparing-anx005-treatment-to-intravenous-immunoglobulin-ivig-or-plasma-exchange-pe-in-a-matched-patient-cohort-for-the-treatment-of-guillain-barre-syndrome-gbs
  9. Annexon Biosciences via BioSpace · 2024-06-25. Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting. https://www.biospace.com/annexon-presented-additional-positive-phase-3-results-for-anx005-c1q-targeted-immunotherapy-in-guillain-barre-syndrome-at-the-2024-pns-annual-meeting
  10. BioSpace · 2024-06-04. Annexon's Pivotal Phase III GBS Trial Hits Goal, Tees Up Approval Filing. https://www.biospace.com/annexon-s-pivotal-phase-iii-gbs-trial-hits-goal-tees-up-approval-filing
  11. Journal of the Peripheral Nervous System via PubMed · 2025-03. Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005, a C1q Inhibitor, in Patients With Guillain-Barré Syndrome. https://pubmed.ncbi.nlm.nih.gov/40000167/
  12. Frontiers in Neurology via PubMed · 2025. Evolving understanding of Guillain-Barré syndrome pathophysiology and the central role of the classical complement pathway in axonal injury. https://pubmed.ncbi.nlm.nih.gov/40438570/
  13. Neurology via PubMed · 2003-09-23. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. https://pubmed.ncbi.nlm.nih.gov/14504313/
  14. MedlinePlus, National Library of Medicine. Guillain-Barre Syndrome. https://medlineplus.gov/guillainbarresyndrome.html

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow tanruprubart by email

We'll email you when the FDA acts on tanruprubart and when new trials for Guillain-Barré Syndrome open. Unsubscribe anytime.

You'll get, for Guillain-Barré Syndrome:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site